TenNor Therapeutics Overview

  • Founded

  • 2013

Founded
  • Status

  • Private

  • Employees

  • 38

Employees
  • Latest Deal Type

  • Series D

  • Latest Deal Amount

  • $9.6M

  • Investors

  • 12

TenNor Therapeutics General Information

Description

Developer of innovative drugs for diseases associated with bacterial infections and bacterial dysbiosis. The company's platform offers a multi-targeting product development portfolio for treating diseases associated with gastrointestinal tract infection and dysbiosis, medical device infections, and bacterial vaginosis, enabling users to get new drugs for the treatment of various diseases with unmet needs.

Contact Information

Website
www.tennorx.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 218 Xinghu Street, Building B2/Suite 711
  • Suzhou Industrial Park
  • Suzhou, Jiangsu 215123
  • China
+86 0512 0000 0000

TenNor Therapeutics Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

TenNor Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series D) 05-Jan-2023 $9.6M 000.00 Completed Clinical Trials - General
5. Later Stage VC (Series D) 25-Feb-2022 000.00 000.00 Completed Clinical Trials - General
4. Later Stage VC (Series C) 30-Jun-2020 00.000 000.00 Completed Clinical Trials - General
3. Later Stage VC (Series C) 18-May-2016 0000 0000 Completed Clinical Trials - General
2. Early Stage VC (Series B) 21-Nov-2013 $7M $7M Completed Startup
1. Early Stage VC (Series A) 22-May-2013 Completed Startup
To view TenNor Therapeutics’s complete valuation and funding history, request access »

TenNor Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of innovative drugs for diseases associated with bacterial infections and bacterial dysbiosis. The company's p
Drug Discovery
Suzhou, China
38 As of 2023
000.00
00000000000 000.00

000 00

nim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000 000000000
Barcelona, Spain
00 As of 0000
0000
00.00 0000-00-00
00000000000 0000

000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nul
0000 000000000
New York, NY
00 As of 0000
00000
0000 0000-00-00
00000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

TenNor Therapeutics Competitors (13)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Ona Therapeutics Venture Capital-Backed Barcelona, Spain 00 0000 00000000000 0000
00000000 Venture Capital-Backed New York, NY 00 00000 00000000000 00000
00 000000000000 Formerly VC-backed Durham, NC 000 00000 00000000 00000
00000000 000000000 Venture Capital-Backed Shanghai, China 00000 0000000000 0 00000
0000000 000000 Venture Capital-Backed Barcelona, Spain 00 000.00 000000000000 000.00
You’re viewing 5 of 13 competitors. Get the full list »

TenNor Therapeutics Patents

  • 31

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 7

    Granted

  • 000

    Pending

  • 000

    Expiring in next 12 mo

TenNor Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4028404-A2 Penam derivatives for treating bacterial infections Pending 11-Sep-2019 0000000000
JP-2022548067-A Penam derivatives for treating bacterial infections Pending 11-Sep-2019 000000000
US-11040987-B2 Penam derivatives for treating bacterial infections Active 11-Sep-2019 000000000
US-20210070774-A1 Penam derivatives for treating bacterial infections Active 11-Sep-2019 000000000
US-20200360520-A1 Use of rifamycin-quinolizidone coupling molecule Inactive 15-May-2019 A61P31/04
To view TenNor Therapeutics’s complete patent history, request access »

TenNor Therapeutics Executive Team (3)

Name Title Board Seat Contact Info
Zhenkun Ma Ph.D Founder, Chief Executive Officer & Board Member
Emily Chen Director, Finance
You’re viewing 2 of 3 executive team members. Get the full list »

TenNor Therapeutics Board Members (10)

Name Representing Role Since
Allen Chao Ph.D Newport Healthcare Advisors Board Member 000 0000
Li Zong WuXi Healthcare Ventures Board Member 000 0000
Lianyong Chen Ph.D Frontline BioVentures Board Member 000 0000
Morton Meyerson 2M Companies Board Member 000 0000
Song Gaoguang Self Board Member 000 0000
You’re viewing 5 of 10 board members. Get the full list »

TenNor Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

TenNor Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Broad Resources Hedge Fund Minority 000 0000 000000 0
Bison Capital Financial Holdings Venture Capital Minority 000 0000 000000 0
Galaxy Holdings Holding Company Minority 000 0000 000000 0
Shenzhen GTJA Investment Group Venture Capital Minority 000 0000 000000 0
Yanyuan Capital Group Venture Capital Minority 000 0000 000000 0
You’re viewing 5 of 12 investors. Get the full list »

Ready to get started?

Request a free trial